Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

July 29, 2020July 30, 2020

Plans Advance for Biomarkers Panel to Assess Drug-induced Skeletal Muscle Injury

News

A new panel of four safety biomarkers to assess acute drug-induced skeletal muscle injury in Phase 1 clinical trials has received a positive response from the U.S. Food and ... Read more

July 10, 2020July 10, 2020

Asuragen’s Diagnostic Test for SMA Approved for Use in Europe

News

Asuragen’s diagnostic test for the analysis of genes associated with spinal muscular atrophy (SMA) — called AmplideX SMA Plus Kit — was given the European CE mark, approving it for ... Read more

March 9, 2020May 15, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still ... Read more

February 21, 2020February 21, 2020

SRK-015 Data Continue to Support Potential for SMA, Scholar Rock Says

News

Preclinical and clinical data on SRK-015 continue to support the therapy’s potential to treat spinal muscular atrophy (SMA), developer Scholar Rock said in a press release. Recruitment for a ... Read more

November 15, 2019November 17, 2019

New Screening Kit Quickly and Thoroughly Analyzes SMN1, SMN2 Genes in Lab, Asuragen Says

News

Asuragen has launched the AmplideX PCR/CE SMN1/2 Plus Kit, which according to the company provides the most comprehensive analysis of genes associated with spinal muscular atrophy (SMA) on the ... Read more

November 8, 2019November 17, 2019

Prenatal Blood Test for SMA Now Available in Four Countries in Europe, BillionToOne Announces

News

BillionToOne’s non-invasive prenatal blood test, which helps diagnose hereditary and rare diseases in fetuses, is now available in Germany, Austria, Switzerland, and the Netherlands, the company announced. The test, ... Read more

July 15, 2019August 20, 2019

Prenatal Blood Test for SMA and Other Single-Gene Diseases Now Available, BillionToOne Announces

News

The diagnostics company BillionToOne has launched its first product for commercial and clinical use — a blood test designed to help diagnose hereditary and rare diseases in fetuses. Called UNITY, the ... Read more

July 10, 2019November 19, 2019

Adding Reldesemtiv to Spinraza or Investigational SMN-C1 Improved Muscle Function in SMA Mouse Model

News

Adding reldesemtiv to survival of motor neuron (SMN) restoration therapies — namely Spinraza (nusinersen) or the investigational SMN-C1 (an analogue to risdiplam) — can improve muscle function in a ... Read more

January 11, 2019February 4, 2019

Many Parents Believe Healthcare for Children with SMA Needs Improvement, Study Reports

News

Optimal care of children with spinal muscular atrophy (SMA) requires improving competence and an adequate exchange of knowledge among healthcare professionals, as well maintaining a close dialogue with the ... Read more

December 21, 2018January 4, 2019

Risdiplam Granted EMA’s PRIME Designation for Potential in Spinal Muscular Atrophy

News

The European Medicines Agency has granted a priority medicines, or PRIME, designation to oral therapy candidate risdiplam to treat spinal muscular atrophy (SMA). PRIME designation is intended to encourage the development of ... Read more